- Home
- CAAP vs LGND Comparison
CAAP vs LGND Comparison
Compare CAAP & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | LGND |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | Luxembourg | United States |
| Employees | N/A | 68 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.7B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CAAP | LGND |
|---|---|---|
| Price | $24.29 | $231.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $26.73 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 236.4K | 181.1K |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.80 | $1.25 |
| Revenue Next Year | $2.36 | $19.41 |
| P/E Ratio | ★ $26.35 | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.36 | $98.90 |
| 52 Week High | $30.50 | $247.38 |
Technical Indicators
Market Signals| Indicator | CAAP | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 56.39 |
| Support Level | $23.83 | $180.85 |
| Resistance Level | $26.78 | N/A |
| Average True Range (ATR) | 0.82 | 10.07 |
| MACD | -0.13 | -0.29 |
| Stochastic Oscillator | 5.60 | 34.46 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.